PMN-310 is under clinical development by ProMIS Neurosciences and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PMN-310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PMN-310 overview
PMN-310 is under development for the treatment of Alzheimer’s disease. The drug candidate is developed based on the proprietary discovery platform, consisting of ProMIS and collective coordinates, to successfully identify distinct target epitopes on prion-like strains of misfolded amyloid beta (amyloid precursor protein). It is administered through intravenous route as infusion.
ProMIS Neurosciences overview
ProMIS Neurosciences (ProMIS) is a clinical-stage biotechnology company that focuses on the discovery and development of therapeutic antibodies. The company specializes in medical conditions like multiple system atrophy, amyotrophic lateral sclerosis, and Alzheimer’s disease that are marked by abnormal, misfolded proteins. Its PMN310, a monoclonal antibody (mAb), designated as its first lead product for development in Alzheimer’s disease (AD). The company utilizes its patented technology platform to generate therapeutic antibody candidates that selectively target toxic forms of proteins without interfering with the functions of the healthy proteins. ProMIS is headquartered in Toronto, Ontario, Canada.
For a complete picture of PMN-310’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
